2023年6月14日

圣地亚哥,加利福尼亚,美国圣地亚哥,6月14日,2023(全球通讯社)——Bionano基因组学,Inc .(纳斯达克:BNGO)宣布,其股东批准的所有提议的2023年度会议上提出,今天早些时候举行。最后的投票结果将在当前形式公布,报告将提交给美国证券交易委员会在4天的会议。“我们感谢支持我们的股东在这些代理建议至关重要,”埃里克Holmlin说Bionano博士,总裁兼首席执行官。“我们现在期待着继续执行我们的战略。“关于Bionano Bionano提供基因组分析解决方案,可以使研究人员和临床医生揭示生物学和医学中具有挑战性的问题的答案。公司的使命是改变世界的方式看到基因组通过OGM解决方案,诊断服务和软件。该公司提供OGM在基本解决方案应用程序,平移和临床研究。通过其Lineagen, inc . d / b / Bionano实验室业务,该公司还为患者提供诊断检测临床表现符合自闭症谱系障碍等神经发育障碍。该公司还提供了行业领先的、平台无关的软件解决方案,集下一代测序和微阵列数据设计提供分析、可视化、解释和报告的拷贝数变异,单核苷酸变异和整个基因组的杂合性缺失一个统一视图。该公司另外提供核酸提取和纯化解决方案使用专有等速电泳(ITP)技术。 For more information, visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com. Bionano’s OGM products are for research use only and not for use in diagnostic procedures. Forward-Looking Statements of Bionano Genomics This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “look forward to” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the timing of Bionano’s current report on Form 8-K regarding the final voting results from its Annual Meeting and Bionano’s execution of its strategy. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: global and macroeconomic events, such as recent and potential bank failures, the impact of the COVID-19 pandemic and the ongoing Ukraine-Russian conflict and related sanctions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2022 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. CONTACTS